EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Early pembrolizumab clearance as prognostic biomarker for non‐response in patients with advanced non‐small cell lung cancer

Fenna de Vries iD, Leila-Sophie Otten iD, Berber Piet, Eric J F Franssen, Arthur A J Smit, Michel M van den Heuvel, Rob Ter Heine, DEDICATION‐1 Study Group

International Journal of Cancer · 2025

DOI: 10.1002/ijc.70052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Fenna de Vries und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, OLVG, Amsterdam, North-Holland, The Netherlands. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Health Insurers, Stichting Treatmeds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors have improved survival rates in patients with advanced‐stage non‐small cell lung cancer; however, the majority obtain no long‐term benefits. We investigated pembrolizumab clearance as an early prognostic biomarker and evaluated its accuracy using a limited sampling strategy. Pembrolizumab clearance was calculated using non‐linear mixed effects modeling, and cut points were determined using maximally selected rank statistics. The prognostic value for survival was estimated using univariate Cox regression analysis. Sensitivity, specificity, and positive and negative predictive values were calculated to evaluate the performance in identifying response (defined as disease control at 6 months). The accuracy of a limited sampling strategy was evaluated using MPE and NRSME. Among 303 patients included, 65% experienced disease progression, and 60% died. Patients with pembrolizumab clearance above 0.232 L/day at the first dose were more likely to have disease progression (HR = 1.98, 95% CI [1.21, 3.26], p = .007) or poor survival (HR = 2.04, 95% CI [1.16, 3.59], p = .014). A diminished decrease in clearance (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCarcinoma, Non-Small-Cell LungLung NeoplasmsBiomarkers, TumorImmune Checkpoint InhibitorsAntineoplastic Agents, ImmunologicalHumansFemaleMalePrognosisMiddle AgedAgedDisease ProgressionAged, 80 and overAdult

Stichwörter der Autor:innen

biomarkerimmune checkpoint inhibitorslung cancer

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedBiomarkers, TumorImmune Checkpoint InhibitorsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Pharmacy, OLVG, Amsterdam, North-Holland, The Netherlands.
  • Department of Pharmacy, Research Institute for Medical Innovation, Radboudumc, Nijmegen, Gelderland, the Netherlands.
  • Department of Respiratory Medicine, Research Institute for Medical Innovation, Radboudumc, Nijmegen, Gelderland, the Netherlands.
  • Department of Pulmonology, OLVG, Amsterdam, North-Holland, The Netherlands.
  • Department of Pulmonology, University Medical Center Utrecht, Utrecht, the Netherlands.

ORCID-Profile: Fenna de Vries, Leila-Sophie Otten

Förderung

  • Dutch Health Insurers
  • Stichting Treatmeds

Zitieren

APA

de Vries, F., Otten, L. S., Piet, B., Franssen, E. J. F., Smit, A. A. J., van den Heuvel, M. M., Ter Heine, R., & DEDICATION‐1 Study Group (2025). Early pembrolizumab clearance as prognostic biomarker for non‐response in patients with advanced non‐small cell lung cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.70052

Vancouver

de Vries F, Otten LS, Piet B, Franssen EJF, Smit AAJ, van den Heuvel MM, et al. Early pembrolizumab clearance as prognostic biomarker for non‐response in patients with advanced non‐small cell lung cancer. International Journal of Cancer. 2025. doi:10.1002/ijc.70052

BibTeX
@article{deVries2025,
  author = {de Vries, Fenna and Otten, Leila-Sophie and Piet, Berber and Franssen, Eric J F and Smit, Arthur A J and van den Heuvel, Michel M and Ter Heine, Rob and DEDICATION‐1 Study Group, DEDICATION‐1 Study Group},
  title = {Early pembrolizumab clearance as prognostic biomarker for non‐response in patients with advanced non‐small cell lung cancer},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.70052}
}
Kostenlos starten →